Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

BACKGROUND: We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line pacl...

Descripción completa

Detalles Bibliográficos
Autores principales: De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900694/
https://www.ncbi.nlm.nih.gov/pubmed/33601296
http://dx.doi.org/10.1016/j.esmoop.2021.100054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900694/
https://www.ncbi.nlm.nih.gov/pubmed/33601296
http://dx.doi.org/10.1016/j.esmoop.2021.100054

Ejemplares similares